#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Warm autoimmune haemolytic anaemia Fabry's disease Cardiac arrest Glycogen storage disease type I Cytomegalovirus infection HER2 mutant non-small cell lung cancer Stress cardiomyopathy Myxofibrosarcoma Neurodegenerative disorder Epilepsy Acute lymphocytic leukaemia Gastrointestinal disorder Chronic kidney disease Ichthyosis Leiomyosarcoma More trials…

    Learn about Rare Diseases

    Carcinoid syndrome – Diagnostics Carcinoid syndrome – Treatment Carcinoid syndrome – Life with Disease Synovial sarcoma metastatic – Treatment MELAS syndrome – Basic Information Carcinoid syndrome – Trials in Disease Rosai-Dorfman syndrome – Life with Disease Toxic epidermal necrolysis – Diagnostics Atypical haemolytic uraemic syndrome – Trials in Disease Mantle cell lymphoma stage II – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Talazoparib Mbf-015 Acetylsalicylic Acid Sulfonamides, Urea Derivatives Belinostat PF-07868489 SODIUM SULFIDE NONAHYDRATE ULIXERTINIB Salbutamol Sulfate Ph. Eur. Omp72 Sparsentan Liraglutide Dorocubicel Riboflavin Sodium Phosphate Sar-443579 Ficlatuzumab Tirbanibulin HUMAN FIBROBLASTS Ngm707 Ecopipam Hydrochloride More therapies…

    Learn about Your Condition

    Meningorrhagia Atrial septal defect Sickle cell disease Binge eating Stress urinary incontinence Cardiac failure Procedural pain Anaemia Type V hyperlipidaemia Mite allergy Progressive supranuclear palsy Oesophageal carcinoma Supranuclear palsy Small cell carcinoma Congenital ureteric anomaly More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Renal cell carcinoma

  • Cabozantinib Monitoring for Toxicity Management in Patients with Renal Cell Carcinoma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Cabozantinib
    • Nivolumab
    Italy

  • Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • Belzutifan
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    Czechia Denmark France Germany Greece Italy +3

  • A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.

    Recruiting

    3 1 1
    Investigated Drugs:
    • Belzutifan
    • Lenvatinib
    Belgium Czechia Denmark Finland France Germany +4

  • A study of PF-08634404, ipilimumab, and axitinib in adults with advanced or metastatic kidney cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    • Clear cell renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    • Ipilimumab
    Germany Spain

  • Study of Heart and Blood Vessel Side Effects in Cancer Patients Receiving Immune Checkpoint Inhibitor Drug Combination Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Head and neck cancer
    • Malignant melanoma
    • Renal cell carcinoma
    Investigated Drugs:
    • Atezolizumab
    • Durvalumab
    • Ipilimumab
    Hungary

  • A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Belzutifan
    • Cabozantinib
    • N-(4-Fluorophenyl)-N-(4-((7-Methoxy-6-(Methylcarbamoyl)Quinolin-4- Yl)Oxy)Phenyl)Cyclopropane-1,1-Dicarboxamide
    Austria Belgium Croatia Czechia Denmark France +6
1 2 3 … 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!